Immunoradiometric assay (IRMA) for the determination of the Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) in serum. For research use only, not for use in diagnostic procedures.
The insulin-like growth factor (IGF) system is the primary regulator of normal body growth and regeneration, affecting cell proliferation, differentiation and apoptosis. In addition, the IGF-system appears to modify insulin sensitivity and long-term glucose metabolism. Finally, numerous epidemiological, experimental and clinical data indicate that the IGF-system is also involved in the development of several common cancers as well as frequent diseases such as atherosclerosis and type 2 diabetes mellitus.
IGFBP-3 is the most abundant IGF-binding protein, accounting for as much as 75% or more of the circulating IGF-binding capacity in healthy subjects. IGFBP-3 shares functional properties with IGFBP-5 in that both peptides are able to form high molecular weight ternary complexes of ~150 kilo Dalton with ALS and either IGF-I or –II. However, IGFBP-5 circulates in much lower concentrations than IGFBP-3, and in healthy subjects the ternary complexes carry as much as 90% of IGFBP-3 but only about 50% of IGFBP-5.
- Assay Description:
- 2 hours total incubation time
- Catalog number:
- KIP1171
- configuration:
- Reagents sufficient for 96 determinations
- controls:
- 2 controls, lyophilized
- design:
- Immunoradiometric assay (IRMA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
- Protocol:
- Sample types:
- Serum
- Sample volume:
- 10 μL / determination
- standards:
- 6 calibrators, lyophilized
- Standard range:
- 0 / 380 - 13395 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 17.3 ng/mL
- Species:
- Human
- radioactivity:
- 18.9 µCi (700 kBq)
